Barely Significant
← all excerpts

Hydralazine-Isosorbide Dinitrate Use in Patients With End-Stage Kidney Disease on Dialysis.

Kidney Int Rep · 2022 · PMC9171697 · PMID 35685328

Europe PMCDOI
1
hedged sentence
—
closest p
—
boldest claim

The sentences

showed a trendno p-value reported
Historically, the combination therapy with H-ISDN was first evaluated for HFrEF in the Veterans affairs Vasodilator—Heart Failure Trial I (V-HeFT I) trial where it showed a trend toward improved survival along with a significant improvement in ejection fraction at 8 weeks and 1 year. 9 The African-American Heart Failure Trial (A-HeFT) trial was conducted on the basis of a post hoc analysis of the V-HeFT I trial and showed a 43% reduction in mortality among Black patients wi

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.